PURPOSE: Peritoneal recurrence of ovarian cancer is frequent after primary surgery and chemotherapy and has poor long-term survival. De novo cytoreductive surgery is crucial with the potential to improve prognosis, especially when combined with hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: The sampled data of 40 consecutive patients were retrospectively analyzed. Thirty-one patients were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. RESULTS: No patient was lost in the perioperative period, and the combined procedure was performed with acceptable morbidity. Colon-preserving cytoreductive surgery was associated with reduced morbidity. CONCLUSIONS: Patients suffering from peritoneal recurrence of ovarian cancer should be considered for radical reoperation with HIPEC in a center with expertise in multimodal therapeutic options. Organ-preserving cytoreductive surgery allows complete cytoreduction with the goal of decreasing morbidity.
PURPOSE: Peritoneal recurrence of ovarian cancer is frequent after primary surgery and chemotherapy and has poor long-term survival. De novo cytoreductive surgery is crucial with the potential to improve prognosis, especially when combined with hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: The sampled data of 40 consecutive patients were retrospectively analyzed. Thirty-one patients were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. RESULTS: No patient was lost in the perioperative period, and the combined procedure was performed with acceptable morbidity. Colon-preserving cytoreductive surgery was associated with reduced morbidity. CONCLUSIONS:Patients suffering from peritoneal recurrence of ovarian cancer should be considered for radical reoperation with HIPEC in a center with expertise in multimodal therapeutic options. Organ-preserving cytoreductive surgery allows complete cytoreduction with the goal of decreasing morbidity.
Authors: I Königsrainer; P Aschoff; D Zieker; S Beckert; J Glatzle; C Pfannenberg; S Miller; J T Hartmann; T H Schroeder; B L D M Brücher; A Königsrainer Journal: Zentralbl Chir Date: 2008-10-15 Impact factor: 0.942
Authors: Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris Journal: J Cancer Res Clin Oncol Date: 2009-08-23 Impact factor: 4.553
Authors: A D Stephens; R Alderman; D Chang; G D Edwards; J Esquivel; G Sebbag; M A Steves; P H Sugarbaker Journal: Ann Surg Oncol Date: 1999-12 Impact factor: 5.344
Authors: Ingmar Königsrainer; Derek Zieker; Stefan Beckert; Claus von Weyhern; Stefan Löb; Claudius Falch; Björn L Brücher; Alfred Königsrainer; Jörg Glatzle Journal: Cell Physiol Biochem Date: 2009-05-06
Authors: Ingmar Königsrainer; Philipp Horvath; Florian Struller; Eva Maria Grischke; Diethelm Wallwiener; Alfred Königsrainer; Stefan Beckert Journal: Langenbecks Arch Surg Date: 2014-05-11 Impact factor: 3.445
Authors: Oliver Zivanovic; Dennis S Chi; Qin Zhou; Alexia Iasonos; Jason A Konner; Vicky Makker; Rachel N Grisham; Amy K Brown; Stacy Nerenstone; John P Diaz; Eric D Schroeder; Carrie L Langstraat; Viktoriya Paroder; Yulia Lakhman; Krysten Soldan; Katy Su; Ginger J Gardner; Vaagn Andikyan; Jianxia Guo; Elizabeth L Jewell; Kara Long Roche; Tiffany Troso-Sandoval; Stuart M Lichtman; Lea A Moukarzel; Kimberly Dessources; Nadeem R Abu-Rustum; Carol Aghajanian; William P Tew; Jan Beumer; Yukio Sonoda; Roisin E O'Cearbhaill Journal: J Clin Oncol Date: 2021-05-21 Impact factor: 50.717